Vanguard Global Advisers
ANAB icon

Vanguard Global Advisers’s AnaptysBio ANAB Stock Holding History

Vanguard Global Advisers’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$940K Buy
13,919
+2,165
+18% +$131K ﹤0.01% 1784
2026
Q1 		$652K Buy
+11,754
New +$632K ﹤0.01% 1908

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Vanguard Global Advisers's ANAB Position: Q2 2026 in Review

Vanguard Global Advisers increased its AnaptysBio (ANAB) stake by 18% in Q2 2026, buying an estimated $131K and bringing the position to 13,919 shares worth $940K. The position accounts for ﹤0.01% of the portfolio, ranked #1784.

Vanguard Global Advisers first reported a position in ANAB in Q1 2026 and has held it in 2 quarters since. 212 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

  • Vanguard Global Advisers held 13,919 shares of AnaptysBio worth $940K as of Q2 2026.
  • Vanguard Global Advisers bought 2,165 AnaptysBio shares in Q2 2026, an estimated $131K.
  • AnaptysBio made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1784 holding.
  • Vanguard Global Advisers first reported a position in AnaptysBio in Q1 2026 and has held it in 2 quarters since.
  • 212 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.